4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioVersys AG (BIOV) operates in the Biotechnology industry and is headquartered in Basel, Switzerland with about 33 employees. Its market capitalization is roughly CHF 155 million. In the fiscal year ended 2025-12-31, BIOV reported CHF 1M in revenue and (CHF 22M) in net income.
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | CHF 1M | CHF 0M |
| Gross Profit | (CHF 3M) | (CHF 4M) |
| Operating Income (EBIT) | (CHF 20M) | (CHF 19M) |
| Net Income | (CHF 22M) | (CHF 19M) |
CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | CHF 91M | CHF 35M |
| Total Liabilities | CHF 31M | CHF 24M |
CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIOV viewer.
About TickerBase · Data methodology & sources · Privacy · Terms